Request Demo
Last update 19 Jul 2025
Octenidine hydrochloride/Prednicarbate
Last update 19 Jul 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Octenidine/prednicarbate, Prednicarbate/octenidine, LAS 189961/LAS 189962 + [3] |
Target |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC27H36O8 |
InChIKeyFNPXMHRZILFCKX-KAJVQRHHSA-N |
CAS Registry73771-04-7 |
View All Structures (2)
Related
3
Clinical Trials associated with Octenidine hydrochloride/PrednicarbateNCT01102387
Phase IIa, Two-centre, Randomized, Double Blind Study to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS41003 Versus Corresponding Mono-substances in Patients With Candida Infections in Intertriginous Areas at the Trunk
NCT01096472
Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedis
NCT01020994
Explorative, Double-blind, Randomized, Controlled Multi-center Phase II Study to Evaluate the Efficacy and Safety of Topically Applied LAS41003 Once Daily Versus LAS189962 and LAS189961 in the Treatment of Superficial Infected Eczema
100 Clinical Results associated with Octenidine hydrochloride/Prednicarbate
Login to view more data
100 Translational Medicine associated with Octenidine hydrochloride/Prednicarbate
Login to view more data
100 Patents (Medical) associated with Octenidine hydrochloride/Prednicarbate
Login to view more data
100 Deals associated with Octenidine hydrochloride/Prednicarbate
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Candidiasis | Phase 2 | Germany | 01 Feb 2010 | |
| Tinea Pedis | Phase 2 | Germany | 01 Feb 2010 | |
| Eczema | Phase 2 | Germany | 01 Nov 2009 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free